Related Experiment Video
Updated: Jul 19, 2026
09:44
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Cytokine-based therapies in inflammatory bowel disease
1Cedars-Sinai Medical Center and the UCLA School of Medicine, Los Angeles, California 90048, USA.
Current Opinion in Gastroenterology
|October 7, 2006
Summary
Recent advancements in cytokine-based therapy offer new hope for inflammatory bowel disease (IBD) patients. Research is exploring novel anti-tumor necrosis factor (TNF) agents and other inflammatory pathways for improved IBD treatment.
Area of Science:
- Gastroenterology and Immunology
- Inflammatory Bowel Disease (IBD) Research
- Therapeutic Drug Development
Background:
- Inflammatory bowel disease (IBD) management has seen significant progress.
- Anti-tumor necrosis factor (TNF) therapies are established treatments for Crohn's disease.
- Understanding the inflammatory cascade in IBD is crucial for developing new treatments.
Purpose of the Study:
- To review recent advancements in cytokine-based therapies for IBD.
- To highlight novel therapeutic targets beyond anti-TNF agents.
- To discuss the emerging roles of specific interleukins in IBD pathogenesis.
Main Methods:
- Review of current scientific literature on IBD therapy.
- Analysis of emerging therapeutic strategies targeting inflammatory pathways.
- Focus on advancements in monoclonal antibody and small molecule development.
Main Results:
- Efficacy of anti-TNF monoclonal antibodies in Crohn's disease fuels further research.
- Development of new anti-TNF therapies including thalidomide and PDE4 inhibitors.
- Exploration of proximal inflammatory events, T-cell regulation, and cytokine modulation.
- Growing interest in the role of interleukin (IL)-11, IL-12, and IL-18 in chronic inflammation.
Conclusions:
- Cytokine-based therapy for IBD is rapidly evolving.
- New therapeutic avenues targeting specific cytokines and inflammatory pathways show promise.
- The future of IBD treatment is optimistic with ongoing research and development.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...